|
|
Article: Calcineurin inhibitors
- Article from:
- Dermatology Times
- Article date:
- March 1, 2008
- Author:
CopyrightCopyright Advanstar Communications, Inc. Mar 2008. Provided by ProQuest LLC. (Hide copyright information)
|
Study supports safety of TCIs for to of atopic dermatitis
San Diego - Ongoing research - in particular, case-controlled studies-supports the safety of using topical calcineurin inhibitors (TCIs), particularly as long-term intermittent therapy for either mild-to-moderate or moderate-to-severe atopic dermatitis.
In an interview with Dermatology Times, Lawrence Eichenfield, M.D., professor of pediatrics and dermatology, University of California, chief of pediatric dermatology at Rady Children's Hospital, says that while fewer nondermatologists, such as pediatricians, are turning to TCIs as a treatment for atopic dermatitis, dermatologists continue to utilize the medications.
"Those ...